Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol - PubMed (original) (raw)
Clinical Trial
. 2002 Oct 2;40(7):1248-58.
doi: 10.1016/s0735-1097(02)02134-4.
Affiliations
- PMID: 12383572
- DOI: 10.1016/s0735-1097(02)02134-4
Free article
Clinical Trial
Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol
Marco Metra et al. J Am Coll Cardiol. 2002.
Free article
Abstract
Objective: We compared the hemodynamic effects of dobutamine and enoximone administration before and after long-term beta-blocker therapy with metoprolol or carvedilol in patients with chronic heart failure (HF).
Background: Patients with HF on beta-blocker therapy may need hemodynamic support with inotropic agents, and the hemodynamic response may be influenced by both the inotropic agent and the beta-blocker used.
Methods: The hemodynamic effects of dobutamine (5 to 20 microg/kg/min intravenously) and enoximone (0.5 to 2 mg/kg intravenously) were assessed by pulmonary artery catheterization in 29 patients with chronic HF before and after 9 to 12 months of treatment with metoprolol or carvedilol at standard target maintenance oral doses. Hemodynamic studies were performed after >/=12 h of wash-out from all cardiovascular medications, except the beta-blockers that were administered 3 h before the second study.
Results: Compared with before beta-blocker therapy, metoprolol treatment decreased the magnitude of mean pulmonary artery pressure (PAP) and pulmonary wedge pressure (PWP) decline during dobutamine infusion and increased the cardiac index (CI) and stroke volume index (SVI) response to enoximone administration, without any effect on other hemodynamic parameters. Carvedilol treatment abolished the increase in heart rate, SVI, and CI and caused a rise, rather than a decline, in PAP, PWP, systemic vascular resistance, and pulmonary vascular resistance during dobutamine infusion. The hemodynamic response to enoximone, however, was maintained or enhanced in the presence of carvedilol.
Conclusions: In contrast with its effects on enoximone, carvedilol and, to a lesser extent, metoprolol treatment may significantly inhibit the favorable hemodynamic response to dobutamine. No such beta-blocker-related attenuation of hemodynamic effects occurs with enoximone.
Similar articles
- Prospective crossover comparison of carvedilol and metoprolol in patients with chronic heart failure.
Maack C, Elter T, Nickenig G, LaRosee K, Crivaro M, Stäblein A, Wuttke H, Böhm M. Maack C, et al. J Am Coll Cardiol. 2001 Oct;38(4):939-46. doi: 10.1016/s0735-1097(01)01471-1. J Am Coll Cardiol. 2001. PMID: 11583862 Clinical Trial. - Different responses to dobutamine in the presence of carvedilol or metoprolol in patients with chronic heart failure.
Bollano E, Täng MS, Hjalmarson A, Waagstein F, Andersson B. Bollano E, et al. Heart. 2003 Jun;89(6):621-4. doi: 10.1136/heart.89.6.621. Heart. 2003. PMID: 12748215 Free PMC article. Clinical Trial. - Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure.
Shakar SF, Abraham WT, Gilbert EM, Robertson AD, Lowes BD, Zisman LS, Ferguson DA, Bristow MR. Shakar SF, et al. J Am Coll Cardiol. 1998 May;31(6):1336-40. doi: 10.1016/s0735-1097(98)00077-1. J Am Coll Cardiol. 1998. PMID: 9581729 Clinical Trial. - Beta-blocker treatment of chronic heart failure: comparison of carvedilol and metoprolol.
Maack C, Elter T, Böhm M. Maack C, et al. Congest Heart Fail. 2003 Sep-Oct;9(5):263-70. doi: 10.1111/j.1527-5299.2003.01446.x. Congest Heart Fail. 2003. PMID: 14564145 Review.
Cited by
- Managing beta-blockers in acute heart failure: when to start and when to stop?
Yilmaz MB, Laribi S, Mebazaa A. Yilmaz MB, et al. Curr Heart Fail Rep. 2010 Sep;7(3):110-5. doi: 10.1007/s11897-010-0014-8. Curr Heart Fail Rep. 2010. PMID: 20544326 Review. - Pathophysiology, diagnosis, and treatment of infarction-related cardiogenic shock.
Buerke M, Lemm H, Dietz S, Werdan K. Buerke M, et al. Herz. 2011 Mar;36(2):73-83. doi: 10.1007/s00059-011-3434-7. Herz. 2011. PMID: 21424345 Review. - Optimization and validation of a fast RP-HPLC method for the determination of dobutamine in rat plasma: Pharmacokinetic studies in healthy rat subjects.
Thippani R, Pothuraju NR, Ramisetti NR, Shaik S. Thippani R, et al. J Pharm Anal. 2013 Dec;3(6):434-439. doi: 10.1016/j.jpha.2013.07.003. Epub 2013 Aug 2. J Pharm Anal. 2013. PMID: 29403851 Free PMC article. - β-Receptor blocker influences return of spontaneous circulation and chemical examination in rats during cardiopulmonary resuscitation.
Zhao XJ, Pen Z, Li P, Chen EX, Liu J, Gao YX, Ren YX, Li LJ. Zhao XJ, et al. J Zhejiang Univ Sci B. 2013 Jun;14(6):505-10. doi: 10.1631/jzus.B1200293. J Zhejiang Univ Sci B. 2013. PMID: 23733427 Free PMC article. - Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials.
Metra M, Eichhorn E, Abraham WT, Linseman J, Böhm M, Corbalan R, DeMets D, De Marco T, Elkayam U, Gerber M, Komajda M, Liu P, Mareev V, Perrone SV, Poole-Wilson P, Roecker E, Stewart J, Swedberg K, Tendera M, Wiens B, Bristow MR; ESSENTIAL Investigators. Metra M, et al. Eur Heart J. 2009 Dec;30(24):3015-26. doi: 10.1093/eurheartj/ehp338. Eur Heart J. 2009. PMID: 19700774 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous